Third generation PCI therapeutic saccule support system, preparation method and application

A stent system and therapeutic technology, applied in the field of biomedical engineering, can solve the problems of delayed blood vessel healing, sudden death of patients, and low incidence rate, and achieve the effect of avoiding vascular restenosis, inhibiting restenosis, and avoiding thrombosis

Inactive Publication Date: 2009-12-02
BEIJING ZHONGFU YOUXIN MEDICAL TECH
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After more than ten years of development, this interventional treatment method is a relatively large technical progress from the balloon metal bare stent system to the second-generation drug-eluting balloon stent system. The problem of the first-generation stent is mainly the stent implantation. The incidence of restenosis is higher
The second generation of stents successfully reduced the incidence of restenosis. However, due to the continuous action of drugs on the surface of damaged blood vessels, which inhibited the repair of the intima of the blood vessels, the blood vessels injured by balloon dilatation were not healed. Therefore, a new generation of stents was developed. The third-generation vascular stent, which reduces thrombosis and reduces restenosis, has become an inevitable choice for clinical treatment of ischemic heart disease
Although the incidence of thrombus in the second-generation stent system is not very high, once the thrombus falls off, it will lead to sudden death of the patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Third generation PCI therapeutic saccule support system, preparation method and application
  • Third generation PCI therapeutic saccule support system, preparation method and application
  • Third generation PCI therapeutic saccule support system, preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1 prepares paclitaxel-coated balloon

[0030] 1.1 Dissolving paclitaxel:

[0031] Prepare 75% alcohol, take 20ML, weigh 10Mg of paclitaxel and add to 75% alcohol, stir and shake.

[0032] 1.2 The surface of the balloon is coated with gelatin:

[0033] Take 20ML of 10% gelatin, soak the balloon in it, and let it stand for 30M.

[0034] 1.3 Paclitaxel-coated balloon:

[0035] Put the gelatin-coated balloon into an ultrasonic sprayer, make it rotate, take 10ML of prepared paclitaxel, shake it well, and use a sprayer to evenly spray it on the surface of the balloon. Adjust the spraying time to control the thickness and amount of spraying, and balloons with different thicknesses and drug loadings can be made.

Embodiment 2

[0036] Embodiment 2 prepares cell-coated balloon (EPC coating)

[0037] 2.1 Isolation of MNC (monocytes) from peripheral blood:

[0038] Extract 5-60ML blood from peripheral blood vessels, add compound sodium citrate injection (ACD-A) to add anticoagulant at 1:10, add Histoque-1077 cell separation medium at 1:1, centrifuge at 400g / Min at room temperature for 10 -30Min, washed three times with PBS.

[0039] 2.2 Isolation and purification of CD34+ cells:

[0040] CD34+ cells were purified using a magnetic activated cell sorting system. 1×105-1×1010 MNCs (monocytes) were suspended in 30ul, 4°C demagnetized PBE buffer (containing 2mmol / LEDTA, 0.5% bovine serum albumin), and 50ul coupled to magnetic beads Mouse anti-human CD34 antibody, incubated at 4°C for 30min. Wash twice with the above buffer, centrifuge at 100×g for 5min, remove unbound antibody, and suspend with 500ul PBE buffer. The magnetic separation column was placed in a magnetic field to sort out magnetic bead-posi...

Embodiment 3

[0053] Example 3 Preparation of antibody-coated balloon (CD34+antibody)

[0054] 3.1 Gelatin, polyisopropylacrylamide gel preparation

[0055] Dissolve 20g of gelatin, 50g of N-isopropylacrylamide, 40ul of tetramethyldiethylamine, 50g of N,N-methylenebisacrylamide (BIS) and 50ml of polyethylene glycol porogen in 1L of deionized water, After it is completely dissolved, add 30ml of ammonium persulfate, and at the same time pass through N2, then add 10ml of glutaraldehyde and stir quickly evenly.

[0056] 3.2 Apply glue to the surface of the balloon

[0057] Put the balloon into the rapidly stirring glue solution, let it stand at room temperature for 2 hours, and take out the balloon.

[0058] 3.3 The antibody is adsorbed on the surface of the balloon (as shown in Figure 6)

[0059] Put the rubber-coated balloon in 12 mg / ml CD34+ antibody, let it stand at 10°C for 50 minutes, take out the stent, put it at 15°C for 2 hours, and sterilize it with ultraviolet light to obtain the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to a third generation PCI therapeutic saccule support system, a preparation method and application, and belongs to the field of biomedical engineering. The therapeutic saccule support treatment system comprises a catheter and a saccule, and is characterized in that the support is a naked support, and a therapeutic medicament and/or a cell coat are attached to the surface of the saccule. After the saccule expansion support is placed into a coronary artery through the catheter, the saccule is expanded through transient pressure so that the medicament or the cell coat on the saccule can tightly cling to the inner wall of a blood vessel so as to repair the blood vessel intima injured by saccule expansion. The system well combines the advantages of the first generation support system and the second generation support system so that the saccule carries the medicament to enter the blood vessel once, and the support is the naked support and only plays a role in supporting the blood vessel so as to well solve the problem of long-term non healing of the injured blood vessel caused by the sustainable medicament of the second generation support system, effectively prevent the formation of thrombus and restrain the occurrence of restenosis.

Description

technical field [0001] The invention relates to the field of biomedical engineering, in particular to a therapeutic balloon and bracket system. Background technique [0002] The most common way to treat ischemic heart disease is PCI (percutaneous coronary intervention). After more than ten years of development, this interventional treatment method is a relatively large technical progress from the balloon metal bare stent system to the second-generation drug-eluting balloon stent system. The problem of the first-generation stent is mainly the stent implantation. The incidence of restenosis is relatively high. The second generation of stents successfully reduced the incidence of restenosis. However, due to the continuous action of drugs on the surface of damaged blood vessels, which inhibited the repair of the intima of the blood vessels, the blood vessels injured by balloon dilatation were not healed. Therefore, a new generation of stents was developed. The third-generation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61F2/82A61F2/86A61M31/00A61L31/16A61L31/02A61L29/08A61L29/16
Inventor 侯东明张建军
Owner BEIJING ZHONGFU YOUXIN MEDICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap